The global biosimilars market is rising with a swift phase; mainly owing to enhanced productivity and clinical trial activities for biosimilars and increasing demand for the cheap medical products. There are many recently development due to the expiry of patient of original drugs. In 2015, The U.S. Food and Drug Administration approved Erelzi, (etanercept-szzs) for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998 and in 2016, FDA approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.
Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/1329
Companies are continuously invent new products to capture the market globally. Thus major players invest more in research and development activity, in order to lead the global market. In this regards, Pfizer Inc., in 2016 announced that it has acquired Bamboo Therapeutics, Inc., in order to lead the market. This acquisition combines the technology and research & development and enhance potentially life-changing therapies. PF-05280014, PF-05280586 and PF-06410293 are under biosimilars clinical trials. It is third largest contributor for biosimilars market. Also In 2016, Teva and Celltrion announce exclusive biosimilar commercial partnership. Teva Pharmaceutical share around 20 % of total global biosimilars market.
Sandoz International GmbH, is the global leader in biosimilars. This company shares 11 % of total global biosimilars market. Increasing need of the better treatment and rising investment and funds for research and development have driven the global market. Moreover companies from developed region are majorly focus in export the drugs to emerging market of Asia Pacific region, As countries from these region have more focus to avail effective treatment at reasonable rate.
Market Segmentation:
The global biosimilars market Share has been segmented on the basis of product, application and manufacturing. Based on product, the biosimilars market is segmented into recombinant glycosylated proteins, recombinant non-glycosylated proteins and others. The recombinant glycosylated proteins segment includes monoclonal antibody (mAb) and EPO. The recombinant non-glycosylated proteins segment is sub-segmented into insulin, growth hormones and others. Based on application, the biosimilars market is segmented into immune diseases, oncology, blood related disorders and others. Based on manufacturing, the biosimilars market is segmented into contract manufacturing and in-house manufacturing.
Regional Analysis:
Geographically, the global biosimilars market has been segmented into four major regions such as North America, Asia Pacific, Europe and the Middle East and Africa. Among these, the Europe region is projecting dominance over the global biosimilars market owing to the rise in research and development activities in the healthcare sector and high healthcare expenditure by the population of this region. With respect to market size, the North America region stands second in the global biosimilars market. The high prevalence of chronic and acute diseases and easy adoption of advanced technology for diagnosis of these diseases in the well-developed healthcare sector is majorly driving the biosimilars market in the North America region. The biosimilars market in the Asia Pacific region is projecting significant growth owing to increasing demand for advanced diagnostic techniques and increasing prevalence of chronic diseases in this region.
Key Players:
The prominent players profiled by MRFR in the report on the global biosimilars market are Pfizer Inc. (the U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Sandoz International GmbH (Germany), Celltrion, Inc. (South Korea), Astra Zeneca (the UK), Amgen Inc. (the U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Biocon Ltd. (India), Dr. Reddy’s Laboratories Ltd. (India), Novartis (Switzerland), Accord Healthcare (the U.K.), Eli Lilly (the U.S.) and Samsung Bioepis (South Korea).
Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
Browse Complete Report @ https://www.marketresearchfuture.com/reports/biosimilars-market-1329
Related reports link:-
3D Printing Medical Devices Market
Breast Imaging Market
Breast Biopsy Market
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
